Osagie Eribo

Mr. Osagie Eribo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2022 in Infection and Immunity
Verified
Journal Article
Closed access
OEOsagie Eribo
Osagie Eribo
NPNelita du Plessis
Nelita du Plessis
NCNovel N Chegou
Novel N Chegou
The gut microbiota has emerged as a critical player in host health.Bacteroides fragilisis a prominent member of the gut microbiota within the phyla Bacteroidetes. This commensal bacterium produces unique capsular polysaccharides processed by antigen-presenting cells and activates CD4+T cells to secrete inflammatory cytokines.

1 October 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
OEOsagie Eribo
Osagie Eribo
MLMonkoe S. Leqheka
Monkoe S. Leqheka
SMStephanus T. Malherbe
Stephanus T. Malherbe
SMShirley McAnda
Shirley McAnda
KSKim Stanley
Kim Stanley
NCNovel N Chegou
Novel N Chegou
To investigate the potential of host urinary biomarkers as diagnostic candidates for tuberculosis (TB). Adults self-presenting with symptoms requiring further investigation for TB were enrolled in Cape Town, South Africa. Participants were later classified as having TB or other respiratory diseases (ORD) using results from TB confirmatory tests. The concentrations of 29 analytes were evaluated in urine samples from participants using the Luminex platform, and their diagnostic potential was assessed using standard statistical approaches. Of the 151 study participants, 34 (22.5%) were diagnosed with TB and 26 (17.2%) were HIV-positive. Seven biomarkers showed potential as TB diagnostic candidates, with accuracy improving (in HIV-positives) when stratified according to HIV status (area under the receiver operating characteristics curve; AUC ≥0.80). In HIV-positive participants, a four-marker biosignature (sIL6R, MMP-9, IL-2Ra, IFN-γ) diagnosed TB with AUC of 0.96, sensitivity of 85.7% (95% confidence interval (CI) 42.1-99.6%), and specificity of 94.7% (95% CI 74.0-99.9%). In HIV-negatives, the most promising was a two-marker biosignature (sIL6R and sIL-2Ra), which diagnosed TB with AUC of 0.76, sensitivity of 53.9% (95% CI 33.4-73.4%), and specificity of 79.6% (95% CI 70.3-87.1%). Urinary host inflammatory biomarkers possess TB diagnostic potential but may be influenced by HIV infection. The results of this study require validation in larger studies.

10 February 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
OEOsagie Eribo
Osagie Eribo
CNCharissa Naidoo
Charissa Naidoo
GTGrant Theron
Grant Theron
GWGerhard Walzl
Gerhard Walzl
NPNelita du Plessis
Nelita du Plessis
NCNovel N Chegou
Novel N Chegou
Bacteroides fragilis is a commonly investigated commensal bacterium for its protective role in host diseases. Here, we aimed to develop a reproducible antibiotic-based model for conditioning the gut microbiota and engrafting B. fragilis into a conventional murine host. Initially, we selected different combinations of antibiotics, including metronidazole, imipenem, and clindamycin, and investigated their efficacy in depleting the mouse Bacteroides population. We performed 16S rRNA sequencing of DNA isolated from fecal samples at different time points. The α-diversity was similar in mice treated with metronidazole (MET) and differed only at weeks 1 (p = 0.001) and 3 (p = 0.009) during metronidazole/imipenem (MI) treatment. Bacteroides compositions, during the MET and MI exposures, were similar to the pre-antibiotic exposure states. Clindamycin supplementation added to MET or MI regimens eliminated the Bacteroides population. We next repeated metronidazole/clindamycin (MC) treatment in two additional independent experiments, followed by a B. fragilis transplant. MC consistently and reproducibly eliminated the Bacteroides population. The depleted Bacteroides did not recover in a convalescence period of six weeks post-MC treatment. Finally, B. fragilis was enriched for ten days following engraftment into Bacteroides-depleted mice. Our model has potential use in gut microbiota studies that selectively investigate Bacteroides’ role in diseases of interest.

29 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OEOsagie Eribo
Osagie Eribo
EGElsje-Marie Geldenhuys
Elsje-Marie Geldenhuys
MOMumin Ozturk
Mumin Ozturk
NANasiema Allie
Nasiema Allie
MNMargaret B Nolan
Margaret B Nolan
NCNovel N Chegou
Novel N Chegou
Background: Anti-tuberculosis (anti-TB) antibiotics alter the gut microbiome, potentially affecting the host physiology and immune response. Here, we investigated the impact of anti-TB antibiotics on host gut microbiota, immune response, and Mtb control. Methods: We pre-treated mice with isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) for two months, followed by intranasal Mtb infection five days post-HRZE cessation. HRZE pre-treated mice received faecal microbiota transplants (FMT) or phosphate-buffered sa-line (PBS) pre- and post-infection. Faecal DNA was isolated, and 16S rRNA gene se-quencing was performed. Mycobacterial burden, histology, and immune response were assessed in tissues four weeks post-infection. Results: We observed an enrichment of Bacteroides, Alistipes, Alloprevotella, Paraprevotella, and Colidextribacter, and depletion of Clostridia UCG 014, Roseburia, Ruminococcus, and Rikenellaceae RC9 gut group in HRZE pre-treated Mtb-exposed mice compared to infected mice without HRZE (control group). HRZE pre-treatment followed by Mtb infection was associated with marked ileal histo-morphological damage compared to infection alone. Furthermore, gut microbiota alter-ations in HRZE pre-treated mice were associated with poor control of the mycobacterial burden, reduced frequencies of CD4+ T and CD68+ macrophage cell populations, and altered release of IFN-γ, IL-6, and PD-1. Notably, although not completely, FMT improved ileal features, normalised microbiota taxa abundance, lowered Mtb burden, and rescued impaired immune phenotypes. Conclusions: These data highlight the untoward con-sequences of recent anti-TB antibiotics for host control of subsequent Mtb infection and suggest a potential therapeutic avenue for mitigating the effects of HRZE-induced mi-crobiota dysbiosis through FMT or probiotics-associated host-directed therapies to prevent TB recurrence.